Navigation Links
New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
Date:10/15/2007

was an international, multi-center, randomized, double-blind, placebo-controlled trial of patients naive to Lamictal, 13 years of age or older who were experiencing eight or more partial seizures during the eight- week baseline period despite taking a stable regimen of one or two antiepileptic drugs (AEDs). Two hundred and thirty-nine patients were randomized to receive either once-daily Lamictal XR or placebo (118 Lamictal XR, 121 placebo). The 19-week treatment period of the study consisted of a seven-week Escalation Phase and a 12-week Maintenance Phase.

The study's primary endpoint was median percent reduction from baseline in partial seizure frequency. Study results showed that Lamictal XR significantly reduced partial seizures by 46.1 percent, compared to 24.2 percent with placebo over the entire 19-week treatment period (P=0.0004). The study also showed significant overall reduction in seizure frequency with Lamictal XR in both the Escalation and Maintenance treatment phases of the study (P=0.028 and P=0.0001, respectively).

The percentage of patients who achieved a .50 percent reduction in partial seizure frequency during the 19-week treatment phase of the study was also significantly higher in the Lamictal XR group compared to placebo (42.2 percent versus 24.2 percent). In addition, the time to achieve and maintain a .50 percent reduction in partial onset seizure frequency was significantly shorter for the group treated with Lamictal XR compared to placebo. Statistical significance was evident at Day 18 and was maintained throughout the 19-week treatment phase of the study.

The median percent reduction from baseline in weekly frequency of secondarily generalized seizures was also significantly higher in patients receiving Lamictal XR compared to placebo (55.2 percent vs. 3.2 percent). Similar results were observed for the escalation and maintenance phases of the study.

The percentage of patients with at least one adverse event during
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... , September 12, 2014 ... Market by Application [Beverages (Alcoholic, CSD, Sports & Energy ... Pet Food, Meat & Seafood)], by Material (Aluminum ... by MarketsandMarkets, defines and segments the Food & ... of each application in terms of volumes and ...
(Date:9/12/2014)... , Sept. 12, 2014 /PRNewswire-iReach/ -- 9 th ... 22-24, 2014 – Bethesda, MD ... http://www.fdanews.com/9thInspectionsSummitEarlyBird   Photo - http://photos.prnewswire.com/prnh/20140912/145652 ... for the next inspection than to get a glimpse ... during and after an inspection. Come to ...
(Date:9/12/2014)... 12, 2014 Research and Markets ... "Global Medical Technologies Market 2014-2018" report to ... a collective term for software solutions, medical devices, ... health. The Global Medical Technologies market covers active ... In vitro diagnostics technology, dental technology, electromechanical medical ...
Breaking Medicine Technology:Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 2Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 3Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 4FDAnews Announces: Early Bird Registration Discount Ends Sept.19 for 9th Annual Inspections Summit, Oct. 22-24, 2014 2FDAnews Announces: Early Bird Registration Discount Ends Sept.19 for 9th Annual Inspections Summit, Oct. 22-24, 2014 3Global Medical Technologies Market 2014-2018: Key Vendors are GE, Johnson & Johnson, Medtronic, Roche and Siemens 2Global Medical Technologies Market 2014-2018: Key Vendors are GE, Johnson & Johnson, Medtronic, Roche and Siemens 3
... and CAMPBELL, Calif. , May ... sophisticated risk characterization and personalized therapy guidelines for ... of advanced tests, offering an accompanying nutrition program, ... Director stated:  "With appropriate risk characterization and treatment, ...
... May 25 The U.S. Food and Drug Administration approved Lumizyme (alglucosidase ... a rare genetic disorder. , , ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , , , ... an estimated 1 in every 40,000 to 300,000 births. Its primary symptom is ...
Cached Medicine Technology:Health Network Laboratories (HNL) Enters Into License Agreement With Hunter Laboratories to Provide HunterHeart Cardiovascular Disease Management Program. 2FDA Approves New Treatment for Late-Onset Pompe Disease 2FDA Approves New Treatment for Late-Onset Pompe Disease 3
(Date:9/15/2014)... (PRWEB) September 15, 2014 (PRWEB) September 15, 2014 ... not; what the startup business requirements are in each ... new business. , Speakers include industry professionals, such as ... Center in Oakland,CA and cannabis business consultant ... who are already successfully running legal marijuana businesses all ...
(Date:9/14/2014)... Petersburg, FL (PRWEB) September 15, 2014 Skin ... external factors like sun damage and not moisturizing properly. However, ... if skin has been cared for. , Two main reasons ... 2) Loss of hyaluronic acid in the skin , During ... and both of these are responsible for important moisture retention ...
(Date:9/14/2014)... Government support for safe patient handling has ... market , The global patient handling equipment market ... five years. The growth of this market is ... increasing lifestyle diseases such as diabetes and Cardiovascular ... market is driven by factors such as government ...
(Date:9/14/2014)... (HealthDay News) -- Getting enough sleep each night may mean you,re ... a new study suggests. The study included more than 3,700 ... an average of seven years. Those who slept less than ... more likely to have extended absences from work due to illness, ... off from work due to sickness were those who slept between ...
(Date:9/14/2014)... A new DePuy Pinnacle hip lawsuit has been filed by ... Franklin County, Ohio man who underwent hip surgery to remove ... filed against Johnson & Johnson and its subsidiary, DePuy Orthopedics, ... when the Pinnacle Hip device was surgically implanted in his ... hip implant lawsuit , the man underwent a revision surgery ...
Breaking Medicine News(10 mins):Health News:How to Start And Run a Successful Legal Marijuana Business 2Health News:2 Reasons Skin Becomes Dryer with Age and What To Do About It, From Sublime Beauty® 2Health News:2 Reasons Skin Becomes Dryer with Age and What To Do About It, From Sublime Beauty® 3Health News:10.7% CAGR For Patient Handling Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:10.7% CAGR For Patient Handling Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:10.7% CAGR For Patient Handling Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:A Good Night's Sleep May Mean a Good Day's Work 2Health News:Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit Purporteding Risky Revision Surgery Needed Due To Failure of Metal-on-Metal Hip Replacement 2Health News:Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit Purporteding Risky Revision Surgery Needed Due To Failure of Metal-on-Metal Hip Replacement 3Health News:Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit Purporteding Risky Revision Surgery Needed Due To Failure of Metal-on-Metal Hip Replacement 4Health News:Wright & Schulte LLC Files Another DePuy Pinnacle Hip Lawsuit Purporteding Risky Revision Surgery Needed Due To Failure of Metal-on-Metal Hip Replacement 5
... WHAT: 211 San Diego executives will highlight key initiatives the, ... nationwide service, discuss the ... times of need, and honor community leaders for their support and, ... Journey event. 211 San Diego also will, ...
... 11 The Ensign Group, Inc. (Nasdaq: ... Ensign(TM) group of skilled nursing, rehabilitative care services ... will participate in the Eighth Annual JMP Securities ... Ritz-Carlton in San Francisco. (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO )Christopher ...
... Reiterates Going Concern Opinion to Comply with NASDAQ ... Encorium Group, Inc. (Nasdaq: ENCO ... (CRO) that provides design, development, and management capabilities ... of the world,s leading pharmaceutical companies, today announced ...
... - The Westaim Corporation announced today that for the quarter ended ... or 3 cents per share, on revenues of $5.2 million compared ... share, on revenues of $5.2 million in the previous year. The ... was $2.3 million compared to income of $3.2 million for the ...
... This release is available in French . ... immunity, men may not have been dealt an equal hand. ... Institute of the McGill University Health Centre and McGill University, ... men. In fact, the production of estrogen by females could ...
... Trust Incorporated (NYSE: HR ) today announced its ... 2009. This dividend, in the amount of $0.385 per ... record on May 22, 2009. The total dividend of ... operations determined in accordance with GAAP. The Company,s cash ...
Cached Medicine News:Health News:211 San Diego Provides Support to San Diegans in Times of Crisis 2Health News:The Ensign Group to Present at the Eighth Annual JMP Securities Research Conference on May 19th 2Health News:The Ensign Group to Present at the Eighth Annual JMP Securities Research Conference on May 19th 3Health News:Encorium Group Enters into Non-Binding Letters of Intent 2Health News:Encorium Group Enters into Non-Binding Letters of Intent 3Health News:Encorium Group Enters into Non-Binding Letters of Intent 4Health News:Encorium Group Enters into Non-Binding Letters of Intent 5Health News:Westaim announces 2009 first quarter results 2Health News:Westaim announces 2009 first quarter results 3Health News:Equality of the sexes? Not always when it comes to biology 2Health News:Healthcare Realty Trust Announces First Quarter Dividend 2Health News:Healthcare Realty Trust Announces First Quarter Dividend 3Health News:Healthcare Realty Trust Announces First Quarter Dividend 4
Free Estriol (E3) RIA Reproductive Hormones 024-IDC-2000...
Prolactin EIA Reproductive Markers 025-BC-1037...
... (17aOHP) is produced by both the ... has relatively little progestational activity, it ... it is the,immediate precursor to 11-desoxycortisol ... 21-hydroxylation of 17aOHP,measurement of 17aOHP is ...
FSH EIA Reproductive Markers 025-BC-1029 Follicle Stimulating Hormone...
Medicine Products: